Earth Gen-Biofuelの空売り状況は、投資家がEarth Gen-Biofuelの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Earth Gen-Biofuel (OTC:EGBB) 株価情報, 空売り情報

Earth Gen-Biofuel Inc is engaged in the manufacturing of Park Model RV's. Park Model RVs are manufactured homes that are built to qualify as an RV for building regulations but are constructed as permanently placed homes. The company develops plans for homes that could serve the need for residents for the unsheltered housing crisis in many cities through utilizing technology to construct affordable living units.

EARTH GEN-BIOFUEL INC by Earth Gen-Biofuel, Inc.

Earth Gen-Biofuel Inc

Barclays analyst Gena Wang maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $435 to $467.

News

Price Target

Analyst Ratings

VRTX

Barclays Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $467

GSAT

Trading Halt: Halt status updated at 9:40:00 AM ET: Quotation Resumption: New Issue Available

Carrier Global Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) shares are trading lower after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43618132/carrier-reports-strong-2024-results-and-announces-2025-outlook" rel="noreferrer noopener">reported mixed fourth-quarter results</a>.
Net sales rose 19% year over year to $5.148 billion, missing the consensus of $5.275 billion. Net sales included 6% organic growth and 13% net contribution from acquisitions and divestitures.
HVAC sales grew 11% organically, led by strong growth in America. EMEA remained flat organically, while Asia Pacific saw slight gains, driven by Japan and South Asia.
Refrigeration sales declined 6% organically, mainly due to lower North America truck and trailer sales, while other segments remained flat.
GAAP operating profit of $774 million was up over 44% from last year, boosted by a Commercial Refrigeration sale. Adjusted operating&nbsp;profit grew 65% to $678 million, driven by Viessmann, organic growth, and productivity gains.
The operating margin expanded by 255 bps to 15%, and the adjusted operating margin expanded by 370 bps to 13.2%.
The company reported adjusted EPS of $0.54 (+50% YoY), <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">beating the consensus of $0.50.</a>
Operating cash flow for fiscal 2024 totaled $563 million, and capital expenditures were $519 million, resulting in a free cash flow of $30 million.
The company exited the quarter with cash and cash equivalents worth $3.969 billion and net debt of $8.309 billion.
&#8220;The quarter also marked the completion of our portfolio transformation, which resulted in total divestiture proceeds of over $10 billion,&#8221; stated Carrier Chairman &amp; CEO David Gitlin.
&#8220;We successfully acquired and integrated Viessmann Climate Solutions in 2024, giving us the most comprehensive and differentiated global portfolio in our industry. We are well-positioned to deliver strong results in 2025, reinforced by our growing global commercial HVAC backlog supported by the acceleration in data centers, commitment to double-digit aftermarket growth, and leading positions across our businesses,&#8221; added Gitlin.
2025 Outlook: Carrier projects accelerated organic growth in 2025 supported by secular tailwinds, <a href="https://www.benzinga.com/calendars/guidance">continued innovation and double-digit aftermarket growth.</a>
The company expects mid-single-digit organic growth with reported sales between $22.5 billion and $23.0 billion versus the consensus of $23.008 billion. This is offset by a $750 million impact from the Commercial Refrigeration divestiture.
CARR sees adjusted EPS of $2.95 – $3.05 versus the consensus of $2.99, reflecting mid- to high-teens growth and an adjusted operating margin of 16.5%—17.0%.
The company forecasts free cash flow of $2.4 billion—$2.6 billion and plans to repurchase approximately $3 billion in shares.
Price Action: CARR shares are trading lower by 3.34% at $64.02 at the last check Tuesday.
Image via Shutterstock.

Earnings

Equities

Guidance

Buybacks

Movers

CARR

Carrier Global Stock Slips After Mixed Q4, CEO Bets Big On 2025 Growth

Craig-Hallum analyst Anthony Stoss maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Hold and lowers the price target from $78 to $50.

Craig-Hallum Maintains Hold on ON Semiconductor, Lowers Price Target to $50

Barclays analyst Julian Mitchell maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Equal-Weight and raises the price target from $285 to $300.

Barclays Maintains Equal-Weight on Rockwell Automation, Raises Price Target to $300

B of A Securities analyst Jason Gerberry maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $143 to $167.

AXSM

B of A Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $167

B of A Securities analyst Michael McGovern maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Buy and raises the price target from $19 to $21.

LYFT

B of A Securities Maintains Buy on Lyft, Raises Price Target to $21

B of A Securities analyst Sara Senatore maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Neutral and raises the price target from $312 to $316.

B of A Securities Maintains Neutral on McDonald's, Raises Price Target to $316

Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) has outperformed the market over the past 10 years by 6.25% on an annualized basis producing an average annual return of 17.41%. Currently, Texas Roadhouse has a market capitalization of $11.54 billion. 
Buying $100 In TXRH: If an investor had bought $100 of TXRH stock 10 years ago, it would be worth $497.60 today based on a price of $173.05 for TXRH at the time of writing.
<h3>Texas Roadhouse's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739284362_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TXRH

$100 Invested In Texas Roadhouse 10 Years Ago Would Be Worth This Much Today

STAI

ScanTech AI Management Confirms Company Has No Convertible Or Variable Rate Indebtedness And No Dilutive Equity Structure On Balance Sheet

B of A Securities analyst Robert Ohmes maintains Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) with a Buy and raises the price target from $165 to $185.

B of A Securities Maintains Buy on Sprouts Farmers Market, Raises Price Target to $185

Barclays analyst Ryan Macwilliams maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Overweight and raises the price target from $325 to $360.

MNDY

Barclays Maintains Overweight on Monday.Com, Raises Price Target to $360

Macro Economic Events

Economics

Federal Reserve

Fed's Hammack Says Federal Government Debt Is On Unsustainable Path Over Longer Term; Rate Hike Is Not In My Base Case, Economy In Good Position; Unclear How Much 2024 Rate Cuts Have Factored Into; We May Be Close To Neutral Rate

Biotech

Government

Regulations

General

BBIO

BEYONTTRA Receives European Commission Marketing Authorization For BEYONTTRA For Treatment Of ATTR-CM

B of A Securities analyst Steve Byrne maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Buy and lowers the price target from $105 to $87.

B of A Securities Maintains Buy on Bunge Global, Lowers Price Target to $87

Barclays analyst Tim Long maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Equal-Weight and lowers the price target from $14 to $10.

HLIT

Barclays Maintains Equal-Weight on Harmonic, Lowers Price Target to $10

Contracts

ESEA

Euroseas Announces 2-Year Charter Contract Extension For Feeder Containership, M/V EM Hydra; For Minimum Period Of 24 Months And Maximum Period Of 26 Months At Gross Daily Rate Of $19,000

B of A Securities analyst Michael Cherny maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Buy and raises the price target from $21 to $25.

PGNY

B of A Securities Maintains Buy on Progyny, Raises Price Target to $25

B of A Securities analyst Salvator Tiano maintains Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) with a Underperform and lowers the price target from $54 to $48.

B of A Securities Maintains Underperform on Archer-Daniels Midland, Lowers Price Target to $48

Results demonstrate that CELZ-201 achieved an 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels, with no serious adverse effects reported.

Comments

Earth Gen-Biofuel

空売り

Earth Gen-Biofuel (OTC:EGBB) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル